Compound Profile
PT 141 (Bremelanotide)
Melanocortin receptor agonist peptide
PT 141 is the research chemical name for bremelanotide, a melanocortin receptor agonist with an actual FDA approved product (Vyleesi) for hypoactive sexual desire disorder in premenopausal women; most gray market marketing (including to men, for erectile dysfunction) extends well beyond that narrow approved indication on much thinner evidence.
Last reviewed:
B ModerateMonograph visual
PT 141 (Bremelanotide)
Generated profile category visual
Where to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Approved drug exists, but research-chemical product is a separate category
Bremelanotide is FDA-approved as Vyleesi, prescription-only, for hypoactive sexual desire disorder (HSDD) in premenopausal women specifically. PT-141 sold as a research chemical is a different regulatory category, not FDA-approved for any use outside that narrow indication, and is not legally intended for human consumption.
- Off-label marketing (e.g., male sexual enhancement, general libido) is not backed by the trial data that supports the approved indication.
- Can transiently raise blood pressure; relevant for anyone with cardiovascular risk factors.
- This profile is not a self-treatment guide.
Regulatory status
2026 federal and state regulatory context
Vyleesi (bremelanotide) is FDA approved prescription only for HSDD in premenopausal women. RUO labeled PT 141 product is not legally intended for human consumption and is not the same regulatory entity as Vyleesi.
Quick Stats
Evidence level
Moderate evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Use caution
Best for
Melanocortin Receptor (MC3R/MC4R) Agonism, Central Nervous System Arousal Pathway Activation
Avoid / review if
Uncontrolled Hypertension, Pregnancy/Breastfeeding, Use In Postmenopausal Women Is Not Well Studied
Safety & Cautions
Review before use if any apply: Uncontrolled Hypertension, Pregnancy/Breastfeeding, Use In Postmenopausal Women Is Not Well Studied.
Evidence-based safety
Caution when combined
These pairings share a flagged risk mechanism. They are additive-effect cautions derived from contraindication data, not confirmed clinical interactions. Consult a clinician before combining.
Moderate Caution
81 flagged pairingsBlood-pressure effects
Moderate Caution
81 flagged pairingsBlood-pressure effects
Browse the grouped cautions below. The list scrolls inside this card when long.
- Agmatine sulfate
- ajoene
- Allicin
- American Ginseng Extract
- Andrographis
- Angelica Dahurica
- Astaxanthin
- Astragalus Membranaceus
- Beetroot extract
- Berberis
- Bicarbonate
- Black Seed
- Black Seed Oil
- Brassica Oleracea
- Buckwheat
- Caffeine
- Capsicum
- Caraway
- Chuanxiong
- Citicoline
- Citrus Bergamia
- Cnidium Monnieri
- Coenzyme Q10
- Coffee Cherry
- Coleus Forskohlii
- Hawthorn
- crocetin
- crocin
- Crocus Sativus
- Cymbopogon Citratus
- Dandelion
- Danshen
- Dendrobium
- Devils Claw Extract
- Electrolyte Mix
- Sodium electrolytes
- Eleuthero
- EGCG
- Epimedium
- Epimedium Brevicornum
- Eucommia
- ferulic acid
- forskolin
- Garlic Extract
- Gastrodia
- Panax Red Ginseng
- Panax White Ginseng
- Glycyrrhiza Glabra
- Guarana
- Guayusa
- Hibiscus
- Huperzia Serrata
- L-Tyrosine
- Lemongrass
- Licorice
- Ligusticum Chuanxiong
- Lobelia Inflata
- Luo Han Guo
- Moringa
- Mucuna
- Myristica Fragrans
- Nettle Root
- Nicotiana Glauca
- Nicotiana Tabacum
- Nigella Sativa
- Nicotinamide Mononucleotide
- Notoginseng
- Olive Leaf
- Olive Leaf Extract
- Panax Ginseng Extract
- Parsley
- Poria
- Punarnava
- Quercetin Phytosome
- Saffron Extract
- Sodium
- Soursop
- Ashwagandha
- Yerba Mate
- Yohimbe
- Yohimbine
Evidence Summary
B ModerateEvidence lens
Useful signal, but study design, dose, and population still matter.
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped — Melanocortin Receptor (MC3R/MC4R) Agonism · Central Nervous System Arousal Pathway Activation
Research maturity: More interpretable — main contexts: Melanocortin Receptor (MC3R/MC4R) Agonism · Central Nervous System Arousal Pathway Activation
Safety boundary: Safety note available — Review before use if any apply: Uncontrolled Hypertension, Pregnancy/Breastfeeding, Use In Postmenopausal Women Is Not Well Studied.
Confidence estimate based on the design quality and consistency of published clinical trials.
PT 141 (Bremelanotide) has a moderate evidence evidence rating.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
How PT 141 (Bremelanotide) Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How PT 141 (Bremelanotide) Works
Mechanisms & Biological Pathways▼
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the PT 141 (Bremelanotide) evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
⚠️ Sourcing Options Disabled for Safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Compound profile context
How to interpret PT 141 (Bremelanotide)
PT 141 dosage by use case, onset and duration, safety limits, and interactions for melanocortin receptor (mc3r/mc4r) agonism, graded against research.… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing PT 141 (Bremelanotide), separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.